Europe’s Largest Industry-Led & Dedicated Gathering for mRNA Leaders
With GSK’s €1.4Bn investment into acquiring CureVac’s infectious disease pipeline, Moderna and BioNTech’s initiation of personalised cancer vaccine trials, and the emergence of novel mRNA applications in protein replacement therapy, gene editing and in vivo cell engineering, the mRNA industry is observing huge value R&D opportunities that will open the floodgates towards clinical and market approval in 2025.
The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for mRNA therapy and vaccine R&D pipelines.
Whether you’re entering the mRNA arena for the first time or a well-seasoned mRNA veteran, with two dedicated tracks of content spanning discovery through commercialisation, this forum will equip you with the know-how and connections to make rapid advances in your work with partnering and collaborative networking opportunities spread throughout.
Assembling 200+ mRNA enthusiasts from across Europe, Asia and the globe, this is your one-stop-shop to gain unparalleled overview of cutting-edge R&D innovations, whilst diving deep into end-to-end development strategy to revolutionise the next wave of mRNA medicines towards clinical reality.
“This is a great opportunity to share current thinking on mRNA therapeutics with regulatory and industry partners from across Europe."
Shirley Hopper, Deputy Director National Licensing Strategy, Medicines and Healthcare Products Regulatory Agency (MHRA)
Among Our 40+ World-Class Speaker Faculty:
Marie Caby-Tosi
European Economic Area/ United Kingdom Qualified Person for Pharmacovigilance
Moderna
Shirley Hopper
Deputy Director National Licensing Strategy
Medicines & Healthcare products Regulatory Agency
Attending Companies Include:
"The mRNA-Based Therapeutics Summit Europe, builds on scientific achievements in this evolving field, brings together stakeholders from various functions to discuss the challenges and opportunities to maximizing the impact of mRNA medicine on people’s health."
Maren von Fritschen, Head of Regulatory Policy Europe, Moderna